Introduction
============

Osteoarthritis (OA) is a major health problem worldwide, and postmenopausal women are one of the most commonly affected groups ([@r1]). Changes in sex steroid hormone levels are a risk factor for development of OA ([@r2]). Besides, it is a widespread disease in reproductive age with an incidence of 4%-12% ([@r3]), increased androgen levels caused by chronic anovulation, and unopposed estrogens are the major laboratory findings in polycystic ovary syndrome (PCOS) ([@r4]). There are many studies pointing to the association of estrogen and androgen hormone levels with cartilage formation in the literature, but the relationship of these hormone levels with development of OA is still unclear. As PCOS is a useful clinical sample to investigate the effect of estrogen and androgen hormone levels on cartilage development, it may help us solve some pathophysiological questions on the development and treatment of OA.

Patients and Methods
====================

Study population
----------------

Study subjects were recruited prospectively from female patients referred to gynecology and orthopedics departments from June to November, 2014. Patients diagnosed with PCOS were selected as study group. Control group included patients with various complaints, admitted to our radiology department for knee ultrasonography (US) examination. The diagnosis of PCOS was made according to the Rotterdam criteria of the American Society of Reproductive Medicine (ASRM) ([@r5]), with evaluation of the presence of oligo/amenorrhea, clinical and biochemical signs of hyperandrogenism, and sonographic confirmation of PCOS. To rule out the possible differences between the groups, all patients were questioned about chronic drug use, smoking, previous knee operations, or trauma. Fertility status and demographic parameters of age, height and weight were also recorded. After careful exclusion, 47 fertile women with PCOS and 43 fertile women without PCOS, matched for age and body mass index (BMI), were enrolled in the study. All patients signed the informed consent form for participation in the study, which received institutional ethical approval and was conducted in line with the Declaration of Helsinki principles.

Ultrasonographic measurements of femoral cartilage
--------------------------------------------------

Thickness of the femoral articular cartilage was measured by Aloca Prosound A6 (Hitachi Aloca Medical, USA) equipped with a 7.5 MHz linear array imaging probe. All measurements were performed by the same radiologists blinded for the patient clinical status while the patient was sitting comfortably on the examination table with the knees in maximum flexion. The probe was placed in the axial plane in the suprapatellar area. Three midpoint measurements were taken from each knee, i.e. from the right lateral condyle, right intercondylar area, right medial condyle, left medial condyle, left intercondylar area and left lateral condyle ([Fig. 1](#f1){ref-type="fig"}).

![Ultrasonographic image demonstrating femoral cartilage measurements (suprapatellar axial view). LCL = lateral condyle; IA = intercondylar area; MC = medial condyle](acc-58-103-f1){#f1}

Statistical analysis
--------------------

All statistical analyses were carried out using the SPSS software program. Categorical variables were compared using the χ^2^-test or Fisher exact test, whereas Student's t test, Mann-Whitney U test and Kruskal-Wallis test were employed to compare the groups. A p value of less than 0.05 was considered statistically significant.

Results
=======

There was no significant difference between the groups in their demographic data ([Table 1](#t1){ref-type="table"}). Measurements of 94 knees in the study group and 86 knees in the control group were analyzed. The mean femoral cartilage thickness at all measurement sites was higher in the study group compared with control group, yielding statistical significance (p\<0.05). These results are shown in [Table 2](#t2){ref-type="table"}.

###### Demographic data of patients

              Study group   Control group   p
  ----------- ------------- --------------- -------
  Age (yrs)   24±3.6        25.8±3.1        0.512
  Height      64±2.9        174±3.1         0.684
  Weight      65±3.2        178±4.1         0.612
  BMI         22±1.9        23±2.1          0.618

BMI = body mass index; p = level of significance

###### Femoral cartilage thickness of patients

        Study group (n=47)   Control group (n=43)   p
  ----- -------------------- ---------------------- -------
  RLC   2.00±0.41            1.76±0.33              0.003
  RIA   2.12±0.51            1.99±0.45              0.002
  RMC   2.15±0.51            2.01±0.22              0.004
  LLC   2.03±0.31            1.812±0.55             0.003
  LIA   2.06±0.28            1.87±0.33              0.002
  LMC   2.20±0.41            2.01±0.12              0.003

p = level of significance; RLC = right lateral condyle; RIA = right intercondylar area; RMC = right medial condyle; LMC = left medial condyle; LIA = left intercondylar area; LLC = left lateral condyle

Discussion
==========

Polycystic ovary syndrome is a common endocrinopathy in reproductive age with an incidence of 4% to 7% ([@r6]), reaching 15% in infertile patients ([@r7]). The main biochemical findings are unopposed levels of estradiol and higher luteinizing hormone/follicle-stimulating hormone ratios, in addition to androgen excess, and these endocrine disorders result in chronic anovulation ([@r8]). The anovulation induces hormonal imbalance and the patient clinical status enters a vicious circle. In this respect, we believed that patients diagnosed with PCOS might provide an appropriate clinical sample to investigate the possible effects of sex steroids on cartilage thickness and OA formation.

Tsai and Liu ([@r9]) report that sex steroids have physiological effects on cartilage involvement, and Abu *et al*. ([@r10]) showed that there were sex steroid receptors located on articular chondrocytes. Previous data indicate that estrogen may conflict with osteoclast and osteoblast coupling and thus the cartilage turnover; it also affects the osteoblast activity on subchondral bone and cartilage *via* second messengers such as transforming growth factor-beta, cartilage-inducing factor A, interleukin-6, and insulin-like growth factor I and II ([@r9], [@r11]-[@r13]). Additionally, previous data suggest that estrogen replacement therapy used for more than 5 years resulted in increased knee cartilage volume ([@r13]), and exogenous estrogen was shown to exert some beneficial effects on OA treatment in animal models ([@r14], [@r15]). However, it is known that men have greater cartilage volume compared with women; we could not assess androgen effects on cartilage volume because of the study population selection. None of our patients showed an androgenic phenotype and further studies are needed to explore the possible impact of androgens on the knee cartilage in PCOS. Another limitation of our study was that our patients had higher BMI values. Since higher weight has an important role in OA formation, our results could not be interpreted as suggesting that PCOS patients had a lower risk of developing OA later in life. We believe that our ongoing long-term follow-up study of PCOS patients will provide answer to this problem.

Since the patients diagnosed with PCOS have greater mean cartilage thickness, we are inclined to believe that the pathophysiological mechanism is based on increased androgen and estrogen hormone values in these patients. Hormone replacement treatment may be useful for OA patients, but further studies are needed to prove our hypothesis.
